Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8N9N8
UPID:
EIF1A_HUMAN
Alternative names:
Eukaryotic translation initiation factor 1A domain-containing protein; Haponin
Alternative UPACC:
Q8N9N8; B2R4N5; Q9BSC1
Background:
The Probable RNA-binding protein EIF1AD, also known as Eukaryotic translation initiation factor 1A domain-containing protein or Haponin, plays a crucial role in cellular response to oxidative stress and regulates cell proliferation. Its unique functions highlight its importance in maintaining cellular homeostasis and response mechanisms.
Therapeutic significance:
Understanding the role of Probable RNA-binding protein EIF1AD could open doors to potential therapeutic strategies. Its involvement in oxidative stress response and cell proliferation control makes it a promising target for developing treatments aimed at enhancing cellular resilience and regulating growth.